"Revolutionary 'Wonder' Drug Offers Breakthrough Treatment for Aggressive Cancers"

Researchers at Queen Mary University of London have developed a new drug, ADI-PEG20, that has shown promising results in treating mesothelioma, a hard-to-treat cancer. The drug, used in combination with chemotherapy, has quadrupled three-year survival rates and increased average survival by 1.6 months in patients. The study, sponsored by Polaris Pharmaceuticals and funded by Cancer Research UK, has been hailed as a significant breakthrough in cancer treatment, offering hope to those affected by mesothelioma.